These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 12928711

  • 21. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients.
    Sugawara Y, Higuchi H, Yoshida K, Takahashi H, Kamata M, Naito S, Sato K, Shimizu T.
    Clin Neuropharmacol; 2006; 29(1):6-9. PubMed ID: 16518126
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
    Higuchi H, Yoshida K, Takahashi H, Naito S, Kamata M, Ito K, Sato K, Tsukamoto K, Shimizu T, Nakanishi M, Hishikawa Y.
    Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression.
    Okumura K, Furukawa TA.
    Clin Drug Investig; 2006 Jun; 26(3):135-42. PubMed ID: 17163244
    [Abstract] [Full Text] [Related]

  • 29. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.
    Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, Itoh K, Ozaki N.
    Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073
    [Abstract] [Full Text] [Related]

  • 30. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H, Yoshida K, Higuchi H, Kamata M, Inoue K, Suzuki T, Ishigooka J.
    Neuropsychobiology; 2014 Mar; 70(3):173-80. PubMed ID: 25358426
    [Abstract] [Full Text] [Related]

  • 31. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G, Milnacipran/Fluvoxamine Study Group.
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [Abstract] [Full Text] [Related]

  • 32. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.
    Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB.
    Am J Psychiatry; 2004 Sep; 161(9):1575-80. PubMed ID: 15337646
    [Abstract] [Full Text] [Related]

  • 33. Milnacipran for fibromyalgia.
    Dempsey J.
    Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
    [Abstract] [Full Text] [Related]

  • 34. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
    Obata H, Saito S, Koizuka S, Nishikawa K, Goto F.
    Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
    [Abstract] [Full Text] [Related]

  • 35. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
    Chang TT, Lêng CH, Wu JY, Lee SY, Wang YS, Chen YC, Lu RB.
    Chin J Physiol; 2008 Dec 31; 51(6):387-93. PubMed ID: 19280883
    [Abstract] [Full Text] [Related]

  • 36. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S, Arita S.
    Hum Psychopharmacol; 2004 Aug 31; 19(6):405-8. PubMed ID: 15303244
    [Abstract] [Full Text] [Related]

  • 37. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R, Ito T, Uchiyama T, Awa Y, Yamaguchi C, Hattori T.
    Urol Int; 2008 Aug 31; 81(3):335-9. PubMed ID: 18931554
    [Abstract] [Full Text] [Related]

  • 38. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E.
    Hum Psychopharmacol; 2004 Dec 31; 19(8):585-6. PubMed ID: 15570574
    [No Abstract] [Full Text] [Related]

  • 39. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
    Bech P, Kajdasz DK, Porsdal V.
    Psychopharmacology (Berl); 2006 Oct 31; 188(3):273-80. PubMed ID: 16960699
    [Abstract] [Full Text] [Related]

  • 40. Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
    Sekine A, Hozumi S, Shimizu T.
    Psychiatry Res; 2016 Aug 30; 242():240-244. PubMed ID: 27294798
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.